D’HASHIMOTO CLASSIQUE
III. Perspectives d’avenir
20. CHEBBAB H, BOUCIF H. MORBIDITE DE LA CHIRURGIE THYROIDIENNE
21. Caron P. Carence iodée: épidémiologie, conséquences, prophylaxie au cours de la grossesse et l'allaitement. Journal de pediatrie et de puericulture. 2007;20(1):9-13.
22. Ingrand J. À propos de l’exploration fonctionnelle thyroïdienne. Immuno-analyse & Biologie spécialisée. 2002;17(3):165-71.
23. Sato H, Grutters JC, Pantelidis P, Mizzon AN, Ahmad T, van Houte A-J, et al. HLA-DQB1* 0201: a marker for good prognosis in British and Dutch patients with sarcoidosis. American journal of respiratory cell and molecular biology. 2002;27(4):406-12.
24. Henderson RD, Bain CJ, Pender MP. The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. Journal of Clinical Neuroscience. 2000;7(5):434-7.
25. Ginn LR, Lin JP, Plotz PH, Bale SJ, Wilder RL, Mbauya A, et al. Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 1998;41(3):400-5.
26. Ohashi PS, Oehen S, Buerki K, Pircher H, Ohashi CT, Odermatt B, et al. Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic mice. Cell. 1991;65(2):305-17.
27. Heath WR, Allison J, Hoffmann MW, Schönrich G, Hämmerling G, Arnold B, et al. Autoimmune diabetes as a consequence of locally produced interleukin-2. Nature. 1992;359(6395):547.
28. Taguchi O, Nishizuka Y. Self tolerance and localized autoimmunity. Mouse models of autoimmune disease that suggest tissue-specific suppressor T cells are involved in self tolerance. Journal of Experimental Medicine. 1987;165(1):146-56.
29. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nature Reviews Immunology. 2002;2(6):389.
30. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, et al. Multiple immuno-regulatory defects in type-1 diabetes. The Journal of clinical investigation. 2002;109(1):131-40.
31. Cao D, Malmström V, Baecher‐Allan C, Hafler D, Klareskog L, Trollmo C. Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. European journal of immunology.
2003;33(1):215-23.
32. Wakkach A, Fournier N, Brun V, Breittmayer J-P, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity. 2003;18(5):605-17.
33. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, et al. Expression of programmed death 1 ligands by murine T cells and APC. The Journal of Immunology. 2002;169(10):5538-45.
34. Bristeau-Leprince A, Mateo V, Lim A, Magerus-Chatinet A, Solary E, Fischer A, et al. Human TCR α/β+ CD4− CD8− double-negative T cells in patients with autoimmune lymphoproliferative syndrome express restricted Vβ TCR diversity and are clonally related to CD8+ T cells. The Journal of Immunology. 2008;181(1):440-8.
35. Hartmann D, Fremeaux-Bacchi V, Weiss L, Meyer A, Blouin J, Hauptmann G, et al. Combined heterozygous deficiency of the classical complement pathway proteins C2 and C4. Journal of clinical immunology. 1997;17(2):176-84.
36. Welch TR, Brickman C, Bishof N, Maringhini S, Rutkowski M, Frenzke M, et al. The phenotype of SLE associated with complete deficiency of complement isotype C4A. Journal of clinical immunology. 1998;18(1):48-51.
37. Brix TH, Knudsen GPS, Kristiansen M, Kyvik KO, Ørstavik KH, Hegedüs L. High frequency of skewed X-chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid autoimmunity. The Journal of Clinical
Endocrinology & Metabolism. 2005;90(11):5949-53.
38. Tonacchera M, Cetani F, Costagliola S, Alcalde L, Uibo R, Vassart G, et al. Mapping thyroid peroxidase epitopes using recombinant protein fragments. European journal of endocrinology. 1995;132(1):53-61.
39. Tomer Y, Greenberg DA, Concepcion E, Ban Y, Davies TF. Thyroglobulin is a thyroid specific gene for the familial autoimmune thyroid diseases. The Journal of Clinical Endocrinology & Metabolism. 2002;87(1):404-.
40. Raspe E, Costagliola S, Ruf J, Mariotti S, Dumont J, Ludgate M. Identification of the thyroid Na+/I− cotransporter as a potential autoantigen in thyroid autoimmune disease. European journal of endocrinology. 1995;132(4):399-405.
41. Marinò M, Pinchera A, McCluskey RT, Chiovato L. Megalin in thyroid physiology and pathology. Thyroid. 2001;11(1):47-56.
42. Kondo T, Nakamura N, Suzuki K, Murata S-i, Muramatsu A, Kawaoi A, et al. Expression of human pendrin in diseased thyroids. Journal of Histochemistry & Cytochemistry. 2003;51(2):167-73.
43. Caillou B, Dupuy C, Lacroix L, Nocera M, Talbot M, Ohayon Re, et al. Expression of reduced nicotinamide adenine dinucleotide phosphate oxidase (ThoX, LNOX, Duox) genes and proteins in human thyroid tissues. The Journal of Clinical Endocrinology & Metabolism. 2001;86(7):3351-8.
44. Rotondi M, Mazziotti G, Biondi B, Manganella G, Del Buono A, Montella P, et al. Long-term treatment with interferon-β therapy for multiple sclerosis and occurrence of Graves’ disease. Journal of endocrinological investigation. 2000;23(5):321-4.
45. Chiovato L, Bassi P, Santini F, Mammoli C, Lapi P, Carayon P, et al. Antibodies producing complement-mediated thyroid cytotoxicity in patients with atrophic or goitrous autoimmune thyroiditis. The Journal of Clinical Endocrinology & Metabolism. 1993;77(6):1700-5.
46. Tomer Y. Anti-thyroglobulin autoantibodies in autoimmune thyroid diseases: cross-reactive or pathogenic? Clinical immunology and immunopathology. 1997;82(1):3-11.
47. Nagayama Y, Wadsworth H, Russo D, Chazenbalk G, Rapoport B. Binding domains of stimulatory and inhibitory thyrotropin (TSH) receptor autoantibodies determined with chimeric TSH-lutropin/chorionic gonadotropin receptors. The Journal of clinical investigation. 1991;88(1):336-40.
48. Fisfalen ME, Palmer EM, van Seventer GA, Soltani K, Sawai Y, Kaplan E, et al. Thyrotropin-receptor and thyroid peroxidase-specific T cell clones and their cytokine profile in autoimmune thyroid disease. The Journal of Clinical Endocrinology & Metabolism. 1997;82(11):3655-63. 49. Davies T. Pathogenesis of Hashimoto’s thyroiditis (chronic autoimmune
50. Battifora M, Pesce G, Paolieri F, Fiorino N, Giordano C, Riccio AM, et al. B7. 1 costimulatory molecule is expressed on thyroid follicular cells in Hashimoto’s thyroiditis, but not in Graves’ disease. The Journal of Clinical Endocrinology & Metabolism. 1998;83(11):4130-9.
51. Salmaso C, Olive D, Pesce G, Bagnasco M. Costimulatory molecules and autoimmune thyroid diseases. Autoimmunity. 2002;35(3):159-67.
52. Paolieri F, Salmaso C, Battifora M, Montagna P, Pesce G, Bagnasco M, et al. Possible Pathogenetic Relevance of Interleukin‐1β in “Destructive” Organ‐specific Autoimmune Disease (Hashimoto's Thyroiditis). Annals of the New York Academy of Sciences. 1999;876(1):221-8.
53. Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science. 1997;275(5302):960-3.
54. Vlaeminck-Guillem V, d'Herbomez-Boidein M, Decoulx M, Wemeau J. Apoptose et thyroïde: le face à Fas. La Presse médicale. 2001;30(2):74-80.
55. Holl R, Bohm B, Loos U, Grabert M, Heinze E, Homoki J. Thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus. Hormone Research in Paediatrics. 1999;52(3):113-8.
56. Tait KF, Gough SC. The genetics of autoimmune endocrine disease. Clinical endocrinology. 2003;59(1):1-11.
57. Vialettes B, Guillerand MA, Viens P, Stoppa A-M, Baume D, Sauvan R, et al. Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies. Acta
endocrinologica. 1993;129(1):31-8.
58. Allen EM, Hsueh W-C, Sabra MM, Pollin TI, Ladenson PW, Silver KD, et al. A genome-wide scan for autoimmune thyroiditis in the Old Order Amish: replication of genetic linkage on chromosome 5q11. 2-q14. 3. The Journal of Clinical Endocrinology & Metabolism. 2003;88(3):1292-6. 59. Vaidya B, Pearce S. The emerging role of the CTLA-4 gene in
autoimmune endocrinopathies. European Journal of Endocrinology. 2004;150(5):619-26.
60. Brix TH, Kyvik KO, Hegedüs L. A population-based study of chronic autoimmune hypothyroidism in Danish twins. The Journal of Clinical Endocrinology & Metabolism. 2000;85(2):536-9.
61. Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M, et al. Positional cloning of the APECED gene. Nature genetics. 1997;17(4):393.
62. Ueda H, Howson JM, Esposito L, Heward J, Chamberlain G, Rainbow DB, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003;423(6939):506.
63. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova J-L, Buist N, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nature genetics. 2001;27(1):18.
64. Sakai K, Shirasawa S, Ishikawa N, Ito K, Tamai H, Kuma K, et al. Identification of susceptibility loci for autoimmune thyroid disease to 5q31–q33 and Hashimoto’s thyroiditis to 8q23–q24 by multipoint affected sib-pair linkage analysis in Japanese. Human molecular genetics. 2001;10(13):1379-86.
65. Zois C, Stavrou I, Kalogera C, Svarna E, Dimoliatis I, Seferiadis K, et al. High prevalence of autoimmune thyroiditis in schoolchildren after elimination of iodine deficiency in northwestern Greece. Thyroid. 2003;13(5):485-9.
66. Eheman CR, Garbe P, Tuttle RM. Autoimmune thyroid disease associated with environmental thyroidal irradiation. Thyroid. 2003;13(5):453-64. 67. En P. farwell Ap, Braverman LE: Thyroiditis. N Engl J Med.
2003;348:2646-54.
68. Bahaoui A. Lupus et grossesse (A propos de 02 cas et revue de la littérature). 2010.
69. Brix TH, Hansen PS, Knudsen GPS, Kringen MK, Kyvik KO, Ørstavik KH, et al. No link between X chromosome inactivation pattern and simple goiter in females: evidence from a twin study. Thyroid. 2009;19(2):165-9. 70. Mayer A, Orgiazzi J. Auto-immunité et thyroide. Encycl Med Chirurg
Endocrinilogie-Nutrition. 2000:1-12.
71. French M, Hughes P. Systemic lupus erythematosus and Klinefelter's syndrome. Annals of the rheumatic diseases. 1983;42(4):471.
72. Tötterman T, Mäenpää J, Gordin A, Mäkinen T, Taskinens E, Andersson L, et al. Blood and thyroid-infiltrating lymphocyte subclasses in juvenile autoimmune thyroiditis. Clinical and experimental immunology. 1977;30(2):193.
73. Akamizu T, Amino N. Hashimoto’s thyroiditis. Endotext [Internet]: MDText. com, Inc.; 2017.
74. Iwatani Y, Hidaka V, Matsuzuka F, Kuma K, Amino N. Intrathyroidal lymphocyte subsets, including unusual CD4+ CD8+ cells and CD3loTCRαβ1o/‐CD4− CD8− cells, in autoimmune thyroid disease. Clinical & Experimental Immunology. 1993;93(3):430-6.
75. Davies TF, Martin A, Concepcion ES, Graves P, Cohen L, Ben-Nun A. Evidence of limited variability of antigen receptors on intrathyroidal T cells in autoimmune thyroid disease. New England Journal of Medicine. 1991;325(4):238-44.
76. Davies T, Concepcion E, Ben-Nun A, Graves P, Tarjan G. T-cell receptor V gene use in autoimmune thyroid disease: direct assessment by thyroid aspiration. The Journal of Clinical Endocrinology & Metabolism. 1993;76(3):660-6.
77. Heuer M, Aust G, Ode-Hakim S, Scherbaum WA. Different cytokine mRNA profiles in Graves' disease, Hashimoto's thyroiditis, and nonautoimmune thyroid disorders determined by quantitative reverse transcriptase polymerase chain reaction (RT-PCR). Thyroid. 1996;6(2):97-106.
78. Gunn A, Michie W, Irvine W. The thymus in thyroid disease. The Lancet. 1964;284(7363):776-8.
79. Michie W, Beck JS, Mahaffy R, Honein E, Fowler G. Quantitative radiological and histological studies of the thymus in thyroid disease. The Lancet. 1967;289(7492):691-5.
80. Mizukami Y, Michigishi T, Hashimoto T, Tonami N, Hisada K, Matsubara F, et al. Silent thyroiditis: a histologic and immunohistochemical study. Human pathology. 1988;19(4):423-31.
81. LiVOLSI VA, Asa SL. The demise of follicular carcinoma of the thyroid gland. Thyroid. 1994;4(2):233-6.
82. JUNJI K, IIDA Y, KASAGI K, MISAKI T, NAKASHIMA T, ENDO K, et al. Primary myxedema with thyrotrophin-binding inhibitor immunoglobulins: clinical and laboratory findings in 15 patients. Annals of internal medicine. 1985;103(1):26-31.
83. Arikawa K, Ichikawa Y, Yoshida T, SHINOZAWA T, Homma M, Momotani N, et al. Blocking type antithyrotropin receptor antibody in patients with nongoitrous hypothyroidism: its incidence and characteristics of action. The Journal of Clinical Endocrinology & Metabolism. 1985;60(5):953-9.
84. Tamai H, Uno H, HIROTA A, HIROTA Y, MATSUBAYASHI S, KUMA K, et al. Immunogenetics of Hashimoto's and Graves5 Diseases. The Journal of Clinical Endocrinology & Metabolism. 1985;60(1):62-6.
85. Roman SH, Greenberg D, Rubinstein P, Wallenstein S, Davies TF. Genetics of autoimmune thyroid disease: lack of evidence for linkage to HLA within families. The Journal of Clinical Endocrinology & Metabolism. 1992;74(3):496-503.
86. Wood LC, Ingbar SH. Hypothyroidism as a late sequela in patients with Graves' disease treated with antithyroid agents. The Journal of clinical investigation. 1979;64(5):1429-36.
87. Bell P, Sinnamon D, Smyth P, Drexhage H, Haire M, Bottazzo G, et al. Hyperthyroidism following primary hypothyroidism in association with polyendocrine autoimmunity. Acta endocrinologica. 1985;108(4):491-7. 88. Tandon N, Yan S, Arnold K, Metcalfe R, Weetman A. Immunoglobulin
class and subclass distribution of eye muscle and fibroblast antibodies in patients with thyroid‐associated ophthalmopathy. Clinical endocrinology. 1994;40(5):629-39.
89. Beck-Peccoz P, Sartorio A, De Medici C, Grugni G, Morabito F, Faglia G. Dissociated thyromimetic effects of 3, 5, 3′-triiodothyroacetic acid (TRIAC) at the pituitary and peripheral tissue levels1. Journal of endocrinological investigation. 1988;11(2):113-8.
90. DAVIES TF, AMINO N. A new classification for human autoimmune thyroid disease. Thyroid. 1993;3(4):331-3.
91. Caturegli P, De Remigis A, Chuang K, Dembele M, Iwama A, Iwama S. Hashimoto's thyroiditis: celebrating the centennial through the lens of the Johns Hopkins hospital surgical pathology records. Thyroid. 2013;23(2):142-50.
92. Li Y, Bai Y, Liu Z, Ozaki T, Taniguchi E, Mori I, et al. Immunohistochemistry of IgG4 can help subclassify Hashimoto's autoimmune thyroiditis. Pathology international. 2009;59(9):636-41.
93. De Luca F, Santucci S, Corica D, Pitrolo E, Romeo M, Aversa T. Hashimoto's thyroiditis in childhood: presentation modes and evolution over time. Italian journal of pediatrics. 2013;39(1):8.
94. Stagnaro-Green A, Pearce E. Thyroid disorders in pregnancy. Nature Reviews Endocrinology. 2012;8(11):650.
95. Konturek A, Barczyński M, Wierzchowski W, Stopa M, Nowak W. Coexistence of papillary thyroid cancer with Hashimoto thyroiditis. Langenbeck's archives of surgery. 2013;398(3):389-94.
96. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon‐alpha induced thyroiditis: toward a new classification. Hepatology. 2006;43(4):661-72.
97. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. The Journal of Clinical Endocrinology & Metabolism. 2013;98(4):1361-75. 98. Vita R, Guarneri F, Agah R, Benvenga S. Autoimmune thyroid disease
elicited by NY-ESO-1 vaccination. Thyroid. 2014;24(2):390-4.
99. Cárdenas-Roldán J, Rojas-Villarraga A, Anaya J-M. How do autoimmune diseases cluster in families? A systematic review and meta-analysis. BMC medicine. 2013;11(1):73.
100. Vladutiu AO, Rose NR. Autoimmune murine thyroiditis relation to histocompatibility (H-2) type. Science. 1971;174(4014):1137-9.
101. Grumet FC, Coukell A, Bodmer JG, Bodmer WF, McDevitt HO. Histocompatibility (HL-A) antigens associated with systemic lupus erythematosus: a possible genetic predisposition to disease. New England Journal of Medicine. 1971;285(4):193-6.
102. Simmonds MJ, Gough SC. The search for the genetic contribution to autoimmune thyroid disease: the never ending story? Briefings in functional genomics. 2011;10(2):77-90.
103. Weetman A, McGregor A. Autoimmune thyroid disease: further developments in our understanding. Endocrine reviews. 1994;15(6):788-830.
104. Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. New England Journal of Medicine. 2001;345(23):1711-2.
105. Vanderpump M, Tunbrldge W, French J, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty‐year follow‐up of the Whickham Survey. Clinical endocrinology. 1995;43(1):55-68.
106. Doniach D, Bottazzo G, Russell R. 6 Goitrous autoimmune thyroiditis (Hashimoto's disease). Clinics in endocrinology and metabolism. 1979;8(1):63-80.
107. Boufaida N, Marhari H, El Ouahabi H, editors. Thyroïdite d’Hashimoto: à propos de 106 cas. Annales d'Endocrinologie; 2017: Elsevier.
108. Katz SM, Vickery Jr AL. The fibrous variant of Hashimoto's thyroiditis. Human pathology. 1974;5(2):161-70.
109. Sostre S, Reyes M. Sonographic diagnosis and grading of Hashimoto’s thyroiditis. Journal of endocrinological investigation. 1991;14(2):115-21. 110. Nordmeyer JP, Shafeh TA, Heckmann C. Thyroid sonography in
autoimmune thyroiditis. A prospective study on 123 patients. Acta endocrinologica. 1990;122(3):391-5.
111. Drahreg01. 2007 [cited 2018]. Available from: https://commons.wikimedia.org/w/index.php?curid=2688708.
112. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid: official journal of the American Thyroid Association. 2003;13(1):3.
113. Beck-Peccoz P, Brucker-Davis Fo, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocrine reviews. 1996;17(6):610-38.
114. Rodien P, Madec A-M, Ruf J, Rajas F, Bornet H, Carayon P, et al. Antibody-dependent cell-mediated cytotoxicity in autoimmune thyroid disease: relationship to antithyroperoxidase antibodies. The Journal of Clinical Endocrinology & Metabolism. 1996;81(7):2595-600.
115. Spencer C. Laboratory support for the diagnosis and monitoring of thyroid disease. Pathology. 2009;41:17.
116. Toubert M. Exploration des marqueurs de l’auto-immunité thyroïdienne. La Thyroïde. 2001;2:289-92.
117. Nøhr SB, Jørgensen A, Pedersen KM, Laurberg P. Postpartum thyroid dysfunction in pregnant thyroid peroxidase antibody-positive women living in an area with mild to moderate iodine deficiency: is iodine supplementation safe? The Journal of Clinical Endocrinology & Metabolism. 2000;85(9):3191-8.
118. Glinoer D. Thyroid autoimmunity and spontaneous abortion. Fertility and sterility. 1999;72(2):373.
119. D’Herbomez M. Exploration biologique de l’auto-immunité thyroïdienne. Bio Tribune Magazine. 2004;9(1):39-41.
120. Feldt-Rasmussen U, Rasmussen AK. Serum thyroglobulin (Tg) in presence of thyroglobulin autoantibodies (TgAb). Clinical and methodological relevance of the interaction between Tg and TgAb in vitro and in vivo. Journal of endocrinological investigation. 1985;8(6):571-6. 121. Spencer C, Takeuchi M, Kazarosyan M, Wang C, Guttler R, Singer P, et
al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism. 1998;83(4):1121-7.
122. McLachlan SM, Rapoport B. Why measure thyroglobulin autoantibodies rather than thyroid peroxidase autoantibodies? Thyroid. 2004;14(7):510-20.
123. Feldt-Rasmussen U. Analytical and clinical performance goals for testing autoantibodies to thyroperoxidase, thyroglobulin, and thyrotropin receptor. Clinical Chemistry. 1996;42(1):160-3.
124. Orgiazzi J. Anti–Tsh Receptor Antibodies in Clinical Practice. Endocrinology and metabolism clinics of North America. 2000;29(2):339-55.
125. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7(3):369-75.
126. Laurberg P, Nygaard B, Glinoer D, Grussendorf M, Orgiazzi J. Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. European Journal of Endocrinology. 1998;139(6):584-6.
127. Endo T, Kogai T, Nakazato M, Saito T, Kaneshige M, Onaya T. Autoantibody against Na+/I− symporter in the sera of patients with autoimmune thyroid disease. Biochemical and biophysical research communications. 1996;224(1):92-5.
128. Sakata S, Matsuda M, Ogawa T, Takuno H, Matsul I, Sarui H, et al. Prevalence of thyroid hormone autoantibodies in healthy subjects. Clinical endocrinology. 1994;41(3):365-70.
129. Pandit AA, Vijay Warde M, Menon PS. Correlation of number of intrathyroid lymphocytes with antimicrosomal antibody titer in Hashimoto's thyroiditis. Diagnostic cytopathology. 2003;28(2):63-5.
130. Carlé A, Laurberg P, Knudsen N, Perrild H, Ovesen L, Rasmussen LB, et al. Thyroid peroxidase and thyroglobulin auto-antibodies in patients with newly diagnosed overt hypothyroidism. Autoimmunity. 2006;39(6):497-503.
131. Rose N. Autoimmune escalation: through the crystal ball. Clin Exp Immunol. 2007;147:9.
132. Chen C-R, Hamidi S, Braley-Mullen H, Nagayama Y, Bresee C, Aliesky HA, et al. Antibodies to thyroid peroxidase arise spontaneously with age in NOD. H-2h4 mice and appear after thyroglobulin antibodies. Endocrinology. 2010;151(9):4583-93.
133. Hutfless S, Matos P, Talor MV, Caturegli P, Rose NR. Significance of prediagnostic thyroid antibodies in women with autoimmune thyroid disease. The Journal of Clinical Endocrinology & Metabolism. 2011;96(9):E1466-E71.
134. Barrère X, Valeix P, Preziosi P, Bensimon M, Pelletier B, Galan P, et al. Determinants of thyroid volume in healthy French adults participating in the SU. VI. MAX cohort. Clinical endocrinology. 2000;52(3):273-8.
135. Mizukami Y, Michigishi T, Kawato M, Sato T, Nonomura A, Hashimoto T, et al. Chronic thyroiditis: thyroid function and histologic correlations in 601 cases. Human pathology. 1992;23(9):980-8.
136. Müller H-W, Schröder S, Schneider C, Seifert G. Sonographic tissue characterisation in thyroid gland diagnosis. Klinische Wochenschrift. 1985;63(15):706-10.
137. Pedersen OM, Aardal NP, Larssen TB, Varhaug JE, Myking O, Vik-Mo H. The value of ultrasonography in predicting autoimmune thyroid disease. Thyroid. 2000;10(3):251-9.
138. KNUDSEN N, BOLS B, BÜLOW I, JØRGENSEN T, PERRILD H, OVESEN L, et al. Validation of ultrasonography of the thyroid gland for epidemiological purposes. Thyroid. 1999;9(11):1069-74.
139. Yeh H-C, Futterweit W, Gilbert P. Micronodulation: ultrasonographic sign of Hashimoto thyroiditis. Journal of Ultrasound in Medicine. 1996;15(12):813-9.
140. Caruso G, Attard M, Caronia A, Lagalla R. Color Doppler measurement of blood flow in the inferior thyroid artery in patients with autoimmune thyroid diseases. European journal of radiology. 2000;36(1):5-10.
141. Davies TF. Ord-Hashimoto's disease: renaming a common disorder— again. Mary Ann Liebert, Inc.; 2003.
142. Huber G, Staub J-J, Meier C, Mitrache C, Guglielmetti M, Huber P, et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. The Journal of Clinical Endocrinology & Metabolism. 2002;87(7):3221-6.
143. Amino N. Autoimmune thyroid disease/thyroiditis. Endocrinology. 1995:726-41.
144. Kothbauer-Margreiter I, Sturzenegger M, Komor J, Baumgartner R, Hess C. Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment. Journal of neurology. 1996;243(8):585-93.
145. TROCELLO J-M. Encéphalopathie corticosensible avec anticorps antithyroïdiens dite encéphalopathie de Hashimoto: faculté de Médecine Paris-Ouest, Université Paris V; 2001.
146. Cantón A, de Fàbregas O, Tintoré M, Mesa J, Codina A, Simó R. Encephalopathy associated to autoimmune thyroid disease: a more appropriate term for an underestimated condition? Journal of the neurological sciences. 2000;176(1):65-9.
147. Ott R, McCall A, McHenry C, Jarosz H, Armin A, Lawrence A, et al. The incidence of thyroid carcinoma in Hashimoto's thyroiditis. The American surgeon. 1987;53(8):442-5.
148. Weiss LM, Weinberg DS, Warhol MJ. Medullary Carcinoma Arising in a Thyroid Hashimoto’s Disease. American journal of clinical pathology. 1983;80(4):534-8.
149. Li Y, Zhou G, Ozaki T, Nishihara E, Matsuzuka F, Bai Y, et al. Distinct histopathological features of Hashimoto’s thyroiditis with respect to IgG4-related disease. Modern pathology. 2012;25(8):1086.
150. 李亜瓊. Distinct clinical, serological, and sonographic characteristics of Hashimoto's thyroiditis based with and without IgG4-positive plasma cells: 和歌山県立医科大学; 2010.
151. Nishimaki M, Isozaki O, Yoshihara A, Okubo Y, Takano K. Clinical characteristics of frequently recurring painless thyroiditis: contributions of higher thyroid hormone levels, younger onset, male gender, presence of thyroid autoantibody and absence of goiter to repeated recurrence. Endocrine journal. 2009;56(3):391-7.
152. Man EB, Jones WS, Holden RH, Mellits ED. Thyroid function in human pregnancy: VIII. Retardation of progeny aged 7 years; relationships to maternal age and maternal thyroid function. American Journal of Obstetrics & Gynecology. 1971;111(7):905-16.
153. Glinoer D, Delange F. The potential repercussions of maternal, fetal, and neonatal hypothyroxinemia on the progeny. Thyroid. 2000;10(10):871-87. 154. Lazarus JH, Ammari F, Oretti R, Parkes AB, Richards CJ, Harris B.
Clinical aspects of recurrent postpartum thyroiditis. Br J Gen Pract. 1997;47(418):305-8.
155. Fatourechi V, McConahey W, Woolner L, editors. Hyperthyroidism associated with histologic Hashimoto's thyroiditis. Mayo Clinic Proceedings; 1971.
156. Wasniewska M, Corrias A, Salerno M, Lombardo F, Aversa T, Mussa A, et al. Outcomes of children with hashitoxicosis. Hormone research in paediatrics. 2012;77(1):36-40.
157. Wiersinga WM. Thyroid hormone replacement therapy. Hormone Research in Paediatrics. 2001;56(Suppl. 1):74-81.
158. de Santé HA. Agence nationale de sécurité du médicament et des produits de santé (ANSM): Stratégie médicamenteuse du contrôle glycémique du diabète de type 2: Recommandation de bonne pratique. Recommandation de bonne pratique. 2013.
159. Barakate MS, Agarwal G, Reeve TS, Barraclough B, Robinson B, Delbridge LW. Total thyroidectomy is now the preferred option for the surgical management of Graves’ disease. ANZ journal of surgery.
2002;72(5):321-4.
160. Reyt V, Buxeraud J. Médicaments des dysfonctionnements thyroïdiens. Actualités Pharmaceutiques. 2018;57(574):1-6.
161. Broome JT, Pomeroy S, Solorzano CC. Expense of robotic thyroidectomy: a cost analysis at a single institution. Archives of Surgery. 2012;147(12):1102-6.
162. Pearce SH, Mitchell AL, Bennett S, King P, Chandran S, Nag S, et al. Adrenal steroidogenesis after B lymphocyte depletion therapy in new-onset Addison's disease. The Journal of Clinical Endocrinology & Metabolism. 2012;97(10):E1927-E32.
163. Jiang S, Camara N, Lombardi G, Lechler RI. Induction of allopeptide-specific human CD4+ CD25+ regulatory T cells ex vivo. Blood. 2003;102(6):2180-6.
164. Tilg H, Van Montfrans C, Van den Ende A, Kaser A, Van Deventer S, Schreiber S, et al. Treatment of Crohn's disease with recombinant human